Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:CVRX NASDAQ:HYPR NYSEAMERICAN:MYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$4.29+13.2%$3.82$1.55▼$4.50$179.58M1.39152,074 shs275,115 shsCVRXCVRx$5.67+5.2%$7.21$4.37▼$11.30$150.48M0.8340,787 shs199,546 shsHYPRHyperfine$1.50+0.3%$1.38$0.66▼$2.22$148.41M1.38544,796 shs558,816 shsMYOMyomo$1.24+12.4%$0.84$0.61▼$3.08$47.76M1.47454,186 shs827,773 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-1.56%-2.82%+23.86%+16.26%+133.95%CVRXCVRx-0.74%-6.75%-32.37%-35.60%-20.27%HYPRHyperfine-0.67%-6.29%-20.32%+36.70%+101.46%MYOMyomo+3.77%+10.00%+22.25%+30.95%-61.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$4.29+13.2%$3.82$1.55▼$4.50$179.58M1.39152,074 shs275,115 shsCVRXCVRx$5.67+5.2%$7.21$4.37▼$11.30$150.48M0.8340,787 shs199,546 shsHYPRHyperfine$1.50+0.3%$1.38$0.66▼$2.22$148.41M1.38544,796 shs558,816 shsMYOMyomo$1.24+12.4%$0.84$0.61▼$3.08$47.76M1.47454,186 shs827,773 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-1.56%-2.82%+23.86%+16.26%+133.95%CVRXCVRx-0.74%-6.75%-32.37%-35.60%-20.27%HYPRHyperfine-0.67%-6.29%-20.32%+36.70%+101.46%MYOMyomo+3.77%+10.00%+22.25%+30.95%-61.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate Buy$6.5051.52% UpsideCVRXCVRx 3.00Buy$11.50102.79% UpsideHYPRHyperfine 2.33Hold$1.7819.29% UpsideMYOMyomo 3.00Buy$7.67520.28% UpsideCurrent Analyst Ratings BreakdownLatest MYO, APYX, HYPR, and CVRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026HYPRHyperfine B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026HYPRHyperfine BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.004/21/2026HYPRHyperfine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CVRXCVRx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026APYXApyx Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/19/2026HYPRHyperfine Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/19/2026HYPRHyperfine Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.503/11/2026APYXApyx Medical Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.003/11/2026APYXApyx Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.003/10/2026MYOMyomo Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$52.84M3.40N/AN/A$0.39 per share11.00CVRXCVRx$56.65M2.66N/AN/A$1.50 per share3.78HYPRHyperfine$11.40M13.02N/AN/A$0.42 per share3.56MYOMyomo$40.93M1.17N/AN/A$0.30 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$11.21M-$0.22N/AN/AN/A-16.40%-88.47%-14.94%8/6/2026 (Estimated)CVRXCVRx-$53.31M-$2.02N/AN/AN/A-89.14%-120.76%-48.38%8/4/2026 (Estimated)HYPRHyperfine-$35.57M-$0.41N/AN/AN/A-226.88%-98.83%-67.09%8/12/2026 (Estimated)MYOMyomo-$15.57M-$0.23N/AN/AN/A-36.69%-119.60%-42.50%8/10/2026 (Estimated)Latest MYO, APYX, HYPR, and CVRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026HYPRHyperfine-$0.09-$0.09N/A-$0.09$3.54 million$3.90 million5/11/2026Q1 2026CVRXCVRx-$0.51-$0.50+$0.01-$0.50$14.49 million$14.77 million5/7/2026Q1 2026APYXApyx Medical-$0.11-$0.05+$0.06-$0.05$10.53 million$12.49 million3/18/2026Q4 2025HYPRHyperfine-$0.08-$0.06+$0.02-$0.06$5.30 million$5.29 million3/10/2026Q4 2025APYXApyx Medical-$0.06-$0.03+$0.03-$0.03$19.12 million$19.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AMYOMyomoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical2.685.804.79CVRXCVRx2.0110.208.89HYPRHyperfine0.385.524.90MYOMyomo1.212.732.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CVRXCVRx75.27%HYPRHyperfine15.03%MYOMyomo44.99%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%CVRXCVRx13.90%HYPRHyperfine26.33%MYOMyomo12.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27041.87 million35.51 millionOptionableCVRXCVRx16026.54 million22.85 millionOptionableHYPRHyperfine19099.27 million73.13 millionOptionableMYOMyomo9038.64 million33.95 millionNot OptionableMYO, APYX, HYPR, and CVRX HeadlinesRecent News About These CompaniesMyomo (NYSEAMERICAN:MYO) Director Buys $24,750.00 in StockJune 2 at 5:34 AM | insidertrades.comMyomo (NYSEAMERICAN:MYO) Insider Sells $20,464.00 in StockJune 1 at 4:57 AM | americanbankingnews.comMyomo (NYSEAMERICAN:MYO) Insider Harry Kovelman Sells 20,464 SharesMay 30, 2026 | insidertrades.comMyomo (NYSEAMERICAN:MYO) Insider Harry Kovelman Sells 11,536 SharesMay 29, 2026 | insidertrades.comMyomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain StockMay 28, 2026 | zacks.comJoseph Jr. Manko Buys 30,367 Shares of Myomo (NYSEAMERICAN:MYO) StockMay 19, 2026 | insidertrades.comMyomo (NYSEAMERICAN:MYO) Insider Sells $77,598.66 in StockMay 16, 2026 | insidertrades.comMyomo Announces Participation in Upcoming Investor ConferencesMay 14, 2026 | finance.yahoo.comMyomo Appoints Joseph M. Manko to its Board of DirectorsMay 13, 2026 | businesswire.comHere Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO)May 12, 2026 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Kiora Pharmaceuticals (KPRX), Myomo (MYO)May 10, 2026 | theglobeandmail.comMyomo, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comMyomo outlines $10.3M-$10.8M Q2 revenue while reiterating $43M-$46M for 2026May 8, 2026 | seekingalpha.comMyomo, Inc. (MYO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comMyomo Earnings Call Shows Steady Gains Amid HeadwindsMay 7, 2026 | tipranks.comMyomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comMyomo Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | businesswire.comMyomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.May 4, 2026 | businesswire.comMyomo to Report First Quarter 2026 Financial Results on May 7May 1, 2026 | businesswire.comMyomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient EngagementApril 21, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYO, APYX, HYPR, and CVRX Company DescriptionsApyx Medical NASDAQ:APYX$4.29 +0.50 (+13.19%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.CVRx NASDAQ:CVRX$5.67 +0.28 (+5.21%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Hyperfine NASDAQ:HYPR$1.50 +0.01 (+0.34%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Myomo NYSEAMERICAN:MYO$1.24 +0.14 (+12.36%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
